National Vaccine Adverse Event Reporting Survey and Etiology

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-03-15

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.

The primary goal of this study is to create a national database and gather vaccine-associated serious adverse events/injury data from newly vaccinated individuals in the US in order to identify the possible underlying causal relationships and plausible underlying biological mechanisms. The project aims to identify the genetic determinants of vaccine-induced adverse response by studying host genetics. We plan to use whole genome sequencing to identify single nucleotide polymorphisms associated with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological symptoms induced by vaccine administration.

The secondary goal is to establish criteria that enable classification of vaccine-induced adverse events/injuries compare data from our database with the official Vaccine Injury Table National Vaccine Injury Compensation Program on or after March 21, 2017.

The tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

NCT05135455

Prevention of Infectious Disease Caused by SARS-CoV-2

COMPLETED

Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.

NCT05228912

Vaccine Adverse Reaction COVID-19 Vaccine Reaction

COMPLETED

Trial to Evaluate the Safety and Immunogenicity of an Anthrax Recombinant Protective Antigen Vaccine

NCT00103467

Prevention of Anthrax Infection

COMPLETED PHASE1

Safety and Immunogenicity Study of Eastern Equine Encephalitis (EEE) Vaccine

NCT00584805

Eastern Equine Encephalitis

COMPLETED PHASE2

A Study of AV0328 Administered to Healthy Adult Volunteers

NCT02853617

PNAG-expressing Pathogenic Microbes Vaccine

COMPLETED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Vaccinations are typically administered to healthy persons and often are mandated by states or federal authorities as a condition for school attendance or military service in order to prevent the spread of infectious diseases. Because vaccines are either mandated or recommended for vulnerable groups, such as children or the elderly, vaccines are often held to a higher standard of safety by the FDA than other medical products.

Due to the vast numbers of vaccine doses administered in the US there is a need to gather quality information on serious vaccine-associated adverse events leading to serious injury. Vaccine-induced adverse events are typically reported in the CDC Vaccine Adverse Event Reporting System (VAERS) database, which contains information on unverified reports of adverse events (illnesses, health problems and/or symptoms) following immunization with US-licensed vaccines. Reports are accepted from anyone and can be submitted electronically at www.vaers.hhs.gov.

The primary goal for this observational study is to establish an independent national database to classify vaccine-associated serious adverse events/injury data from vaccinated individuals. The plan is to gather survey data and health information from newly vaccinated individuals who have experienced serious adverse effects in order to help understand the possible causal relationships and plausible biological mechanisms underlying serious adverse events/injuries. The project aims to identify the genetic determinants of vaccine-induced adverse response by studying host genetics. We plan to use Nebula Genomics platform for whole genome sequencing to identify single nucleotide polymorphisms associated with cardiovascular, neurological, gastrointestinal, musculoskeletal and immunological symptoms induced by vaccine administration.

The secondary goal is to gather medical history and survey data from recently vaccinated individuals in order to develop a vaccine-injury risk assessment tool which may be used to predict individual vulnerability to vaccine adverse events/injury.

The tertiary goal is to establish a database to gather detailed long-term adverse reaction data from subjects enrolled in FDA Emergency Use Authorized vaccine clinical trials.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 Vaccine Adverse Reaction Vaccine Reaction Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use Corona Virus Infection Blood Clot Thrombocytopenia Neuritis Vasculitis Influenza Guillain-Barré GWAS Genetic Sequencing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccinated

All individuals who have received a vaccine dose.

vaccinated

Intervention Type BIOLOGICAL

Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vaccinated

Pfizer-BioNTech COVID-19 Vaccine, Moderna or J\&J/Janssen COVID-19 Vaccine, Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT) Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib) Hepatitis A (e.g., HAV) Hepatitis B (e.g., HBV) Human papillomavirus (e.g., HPV) Seasonal influenza (e.g., Flu) Measles (e.g., MMR) Mumps (e.g., MMR, MR, M) Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C) Pertussis (e.g., DTP, DTaP, Tdap) Pneumococcal conjugate (e.g., PCV) Polio (e.g., OPV or IPV) Rotavirus (e.g., RV) Rubella (e.g., MMR, MR, R) Tetanus (e.g., Td) Varicella (e.g., VAR)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Individuals who have received at least one vaccine dose of ANY of the following vaccines (below) and experienced adverse reaction within 60 days of vaccine administration:

1. Pfizer-BioNTech COVID-19 Vaccine
2. Moderna COVID-19 Vaccine
3. J\&J/Janssen COVID-19 Vaccine
4. Diphtheria (e.g., DTP, DTaP, Tdap, DT, Td, TT)
5. Haemophilus influenza type b polysaccharide conjugate vaccines (e.g., Hib)
6. Hepatitis A (e.g., HAV)
7. Hepatitis B (e.g., HBV)
8. Human papillomavirus (e.g., HPV)
9. Seasonal influenza (e.g., Flu)
10. Measles (e.g., MMR)
11. Mumps (e.g., MMR, MR, M)
12. Meningococcal (e.g., MCV4, MPSV4, MenB-FHbp, MenB-4C)
13. Pertussis (e.g., DTP, DTaP, Tdap)
14. Pneumococcal conjugate (e.g., PCV)
15. Polio (e.g., OPV or IPV)
16. Rotavirus (e.g., RV)
17. Rubella (e.g., MMR, MR, R)
18. Tetanus (e.g., Td)
19. Varicella (e.g., VAR).

Exclusion Criteria

1. Non citizens or permanent residents of the US
2. Individuals who have not received at least one vaccine dose in the past 3 years.
3. Individuals whose vaccine was administered more than 60 days before symptoms of the serious adverse event.

\-

Minimum Eligible Age

5 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No